Monopar Therapeutics Inc
Company Profile
Business description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Contact
1000 Skokie Boulevard
Suite 350
WilmetteIL60091
USAT: +1 847 388-0349
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
World’s largest miner overvalued after solid quarter
stocks
Hidden value in an expensive ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.90 | 26.50 | -0.29% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 26,024.72 | 138.52 | -0.53% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,434.94 | 150.92 | -0.25% |
| NZX 50 Index | 12,873.77 | 71.83 | -0.55% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,788.20 | 31.30 | -0.35% |
| SSE Composite Index | 4,110.48 | 4.23 | 0.10% |